• Exchange: Copenhagen
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech


254.0000 DKK 6.1000 2.46%

As of 12:02:40 ET on 10/30/2014.

Snapshot for Genmab A/S (GEN)

Open: 247.1000 Day's Range: 245.2000 - 254.0000 Volume: 192,791
Previous Close: 247.9000 52wk Range: 180.1000 - 260.0000 1-Yr Rtn: +6.50%

Stock Chart for GEN

No chart data available.
  • GEN:DC 254.0000
  • 1D
  • 1M
  • 1Y
Interactive GEN Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for GEN

Current P/E Ratio (ttm) 96.4183
Estimated P/E(12/2014) 65.2118
Relative P/E vs. KFX 4.4172
Earnings Per Share (DKK) (ttm) 2.6344
Est. EPS (DKK) (12/2014) 3.8950
Est. PEG Ratio 1.4701
Market Cap (M DKK) 14,432.60
Shares Outstanding (M) 56.82
30 Day Average Volume 213,935
Price/Book (mrq) 8.2258
Price/Sale (ttm) 18.4619
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 11/05/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for GEN

  • Revenue
  • Net Income (M/DKK)
  • Profit Margin (%)

Company Profile & Key Executives for GEN

Genmab A/S is a biotechnology company. The Company creates and develops human antibody products for the treatment of life threatening and debilitating diseases. Genmab focuses on products to treat cancer, rheumatoid arthritis and other inflammatory conditions, and psoriasis. The Company develops new products through partnerships. Genmab operates in Europe and the United States.

Jan G J Van De WinkelPresident/CEO/Co-FounderDavid A EatwellExec VP/CFO
Paul W H I ParrenSenior VP/Dir:ScientificMichael K BauerSenior VP:Clinical Development
More Company Profile & Key Executives for GEN

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil